• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glucose monitor maker Know Labs names new CEO, makes other executive changes

January 27, 2023 By Sean Whooley

Know Labs KnowU Uband non-invasive glucose monitor
[Image from Know Labs]
Know Labs (NYSE:KNW) announced that it named Ron Erickson as CEO as the company makes a handful of changes at the top.

The Seattle-based non-invasive glucose monitor maker’s board unanimously named Erickson, its founder and chair, as CEO. Former CEO Phil Bosua stepped down as an executive officer of the company and board member. Know Labs said Bosua will become a technology advisor and consultant to the company, effective immediately.

Erickson founded Know Labs, spending time with the company and its predecessors for nearly 20 years, according to a news release. He brings 30 years of high-level experience across industries including therapeutics, mobile technologies and software.

Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. This technology integrates into wearable, mobile or bench-top form factors. Know Labs developed the first application of Bio-RFID as a non-invasive glucose monitor.

“Having established our Bio-RFID platform technology as a new standard for accuracy in glucose monitoring, as evidenced by our latest patent, our focus now is accelerating product development and testing while working toward the FDA clearance process for medical devices,” Erickson said. “We anticipate our work toward this goal will accelerate in 2023, as a result of the progress made by our team, with support from our investors. We have recently expanded our team in product and clinical development functions, which are critical for our 2023 activities. I’m confident we have the right team to achieve our goals and believe Bio-RFID will transform the medical diagnostics industry and significantly improve the lives of millions of people worldwide.”

Other changes at the top for Know Labs

Know Labs made changes at the chief technology officer, chief marketing officer and chief commercial officer positions.

It named Masanori King Takee as its new CTO. Takee continues to lead Know Labs’ software engineering, AI and machine learning activities. He joined the company in 2018 as one of its first employees and brings 20 years of experience in software creation.

Jessica English joins the Know Labs executive team at the chief marketing officer position. Her responsibilities include leading marketing and communication efforts ahead of an eventual commercial launch. English holds more than 15 years of experience leading brand, marketing and communications strategies, including in health technology.

Know Labs named its previous chief marketing officer, Leo Trautwein, as its new CCO. He runs corporate strategy, operations and regulatory in addition to his efforts in marketing. Trautwein has spent 25 years as a strategy consultant, general manager and P&L leader.

“I’m excited for 2023,” Erickson said. “These changes to our leadership team will allow us to accelerate our progress and collaborate more, while eliminating silos. I have strong trust in this team and believe each one of them can deliver what we need. I welcome Jess to the team and congratulate the others for their contributions and great work performed to date. We are a very collaborative team working toward a common objective, to transform the medical diagnostics industry, and I’m confident we can get there.

Filed Under: Business/Financial News, Diabetes, Featured, Patient Monitoring Tagged With: Know Labs, Personnel Moves

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS